We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software
Read MoreHide Full Article
Key Takeaways
GE HealthCare wins FDA clearance for Critical Care Suite 3.0, expanding AI feeding tube assessment.
GEHC shares gained more than 2% following the news, while the stock has gained 0.2% year to date.
GEHC's AI software achieved 99.2% tube detection sensitivity and operates without cloud connectivity.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently received FDA 510(k) clearance for Critical Care Suite 3.0, an AI-enabled software designed to assist clinicians in assessing feeding tube placement through X-ray imaging. The latest addition to its imaging portfolio extends feeding tube assessment capabilities to both adult and pediatric patients, strengthening the company's presence in AI-enabled diagnostic imaging.
The FDA clearance marks another step forward in GE HealthCare's efforts to integrate AI into its imaging solutions and enhance clinical workflows. Expanding its AI capabilities across patient populations could strengthen the value proposition of its mobile X-ray systems, support customer adoption and reinforce its competitive position in the medical imaging market. Such innovations may also create opportunities for deeper customer relationships and support long-term growth in its imaging business.
GEHC Stock Trend Following the News
Shares of GEHC have gained more than 2% since the announcement on Tuesday. Year to date, the stock has inched up 0.2% against the industry’s 15.2% decline. However, the S&P 500 has risen 5.9% during the same timeframe.
The FDA clearance for Critical Care Suite 3.0 is likely to support GE HealthCare's long-term growth by strengthening its AI-enabled X-ray portfolio and enhancing the clinical value of its mobile imaging systems. Extending feeding tube assessment capabilities to pediatric patients broadens the software's addressable patient population, potentially increasing demand for the company's advanced imaging solutions.
The ability to deliver AI-generated insights directly at the bedside without requiring cloud connectivity could also improve workflow efficiency and differentiate GEHC's offerings from competitors. Over time, continued innovation in AI-enabled imaging may support customer retention, drive adoption of higher-value solutions and reinforce the company's competitive position in the global medical imaging market.
GEHC currently has a market capitalization of $37.51 billion.
Image Source: Zacks Investment Research
More on the News
Critical Care Suite 3.0 is designed to identify the enteric tube path, tip and side port on X-ray images, while highlighting the airways and diaphragm as anatomical reference points. The AI algorithm operates directly on compatible mobile X-ray devices, enabling clinicians to access feeding tube assessment information at the bedside without requiring Internet or cloud connectivity.
In testing, the software demonstrated 99.2% sensitivity for tube detection and 91.6% mean DICE localization, which measures how closely AI-generated outlines match expert radiologist annotations. These capabilities are intended to support clinicians in assessing tube placement and accessing relevant information more efficiently in critical care settings.
Mobile X-ray systems are widely used in emergency departments and intensive care units, accounting for 75% and 51% of mobile X-ray usage in these settings, respectively, according to GE HealthCare. The company also cited research estimating that nearly 80% of ICU patients receive enteral nutrition through nasogastric or nasoenteric tubes, highlighting the clinical relevance of the new capability.
Critical Care Suite 3.0 builds on GEHC's existing portfolio of on-device AI algorithms for automated measurements, case prioritization and image quality control. It also incorporates Quality Care Suite, which uses AI algorithms to help reduce image quality errors and improve workflow efficiency. Emplify Health, an early user of the technology, noted that clinicians value the ability to access feeding tube assessment information at the bedside and frequently request portable X-ray systems equipped with the software.
Industry Prospects Favoring the Market
According to Precedence Research, the global diagnostic imaging market size was calculated at $50.12 billion in 2025 and is predicted to increase from $52.55 billion in 2026 to approximately $80.12 billion by 2035, expanding at a CAGR of 4.80% from 2026 to 2035.
The rising awareness of early disease detection is expected to boost the market growth.
Other News
GE HealthCare recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Image: Bigstock
GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently received FDA 510(k) clearance for Critical Care Suite 3.0, an AI-enabled software designed to assist clinicians in assessing feeding tube placement through X-ray imaging. The latest addition to its imaging portfolio extends feeding tube assessment capabilities to both adult and pediatric patients, strengthening the company's presence in AI-enabled diagnostic imaging.
The FDA clearance marks another step forward in GE HealthCare's efforts to integrate AI into its imaging solutions and enhance clinical workflows. Expanding its AI capabilities across patient populations could strengthen the value proposition of its mobile X-ray systems, support customer adoption and reinforce its competitive position in the medical imaging market. Such innovations may also create opportunities for deeper customer relationships and support long-term growth in its imaging business.
GEHC Stock Trend Following the News
Shares of GEHC have gained more than 2% since the announcement on Tuesday. Year to date, the stock has inched up 0.2% against the industry’s 15.2% decline. However, the S&P 500 has risen 5.9% during the same timeframe.
The FDA clearance for Critical Care Suite 3.0 is likely to support GE HealthCare's long-term growth by strengthening its AI-enabled X-ray portfolio and enhancing the clinical value of its mobile imaging systems. Extending feeding tube assessment capabilities to pediatric patients broadens the software's addressable patient population, potentially increasing demand for the company's advanced imaging solutions.
The ability to deliver AI-generated insights directly at the bedside without requiring cloud connectivity could also improve workflow efficiency and differentiate GEHC's offerings from competitors. Over time, continued innovation in AI-enabled imaging may support customer retention, drive adoption of higher-value solutions and reinforce the company's competitive position in the global medical imaging market.
GEHC currently has a market capitalization of $37.51 billion.
Image Source: Zacks Investment Research
More on the News
Critical Care Suite 3.0 is designed to identify the enteric tube path, tip and side port on X-ray images, while highlighting the airways and diaphragm as anatomical reference points. The AI algorithm operates directly on compatible mobile X-ray devices, enabling clinicians to access feeding tube assessment information at the bedside without requiring Internet or cloud connectivity.
In testing, the software demonstrated 99.2% sensitivity for tube detection and 91.6% mean DICE localization, which measures how closely AI-generated outlines match expert radiologist annotations. These capabilities are intended to support clinicians in assessing tube placement and accessing relevant information more efficiently in critical care settings.
Mobile X-ray systems are widely used in emergency departments and intensive care units, accounting for 75% and 51% of mobile X-ray usage in these settings, respectively, according to GE HealthCare. The company also cited research estimating that nearly 80% of ICU patients receive enteral nutrition through nasogastric or nasoenteric tubes, highlighting the clinical relevance of the new capability.
Critical Care Suite 3.0 builds on GEHC's existing portfolio of on-device AI algorithms for automated measurements, case prioritization and image quality control. It also incorporates Quality Care Suite, which uses AI algorithms to help reduce image quality errors and improve workflow efficiency. Emplify Health, an early user of the technology, noted that clinicians value the ability to access feeding tube assessment information at the bedside and frequently request portable X-ray systems equipped with the software.
Industry Prospects Favoring the Market
According to Precedence Research, the global diagnostic imaging market size was calculated at $50.12 billion in 2025 and is predicted to increase from $52.55 billion in 2026 to approximately $80.12 billion by 2035, expanding at a CAGR of 4.80% from 2026 to 2035.
The rising awareness of early disease detection is expected to boost the market growth.
Other News
GE HealthCare recently announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using its ultra-high-gradient, head-only 3.0T MR system. The alliance will bring together leading researchers and clinicians across multiple disciplines to explore advanced MRI techniques, investigate brain structure and function and develop novel imaging biomarkers that could improve the understanding and diagnosis of neurological conditions.
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.